Kin Meds NAD+ prices
3 figures read September 2026.
Kin Meds publishes a standing rate of $349 for NAD+, but never on a calendar month — it bills on a cycle of its own, and the difference is the whole reason this page prints the seller's own wording for it.
What Kin Meds publishes
Kin Meds publishes a standing rate, but never on a calendar month — it bills every 4 weeks, every 28 days, or across a multi-month term. Of the 11 sellers in this index that fall in the same bucket, that puts it with the 10% of the roster that publishes this shape of number rather than another one. A standing rate charged on a calendar month is the only figure this site treats as a monthly price, and 60 of the 106 sellers in this index — including this one — do not publish one.
The figure above is a standing rate, “30-day supply of the medication, shipped every 30 days.”. This site never prints a price without that qualifier, on any surface, because the same number means a different thing depending on it — and in this corpus the same seller often prints several.
Every figure Kin Meds publishes — 3 figures, read September 2026
| Figure | What it is | Cycle, in their words | Route | Dose | Read |
|---|---|---|---|---|---|
| $249 | from-price | no cycle stated | SubQ | Not stated | September 2026 |
| $349 | from-price | no cycle stated | Nasal | Not stated | September 2026 |
| $349 | standing rate | “30-day supply of the medication, shipped every 30 days.” | Oral | 200 mg troche, 30 count | September 2026markup only — not shown to a reader |
In Kin Meds’s own words
- $249 from-price
The page says: “Starts At $249”
The page says 'injections' and 'Medication shipped directly to your door!' - an at-home injection rather than a clinic drip; it never uses the word subcutaneous and never says IV. No period is attached to the $249 anywhere on the page.
Read from https://kinmeds.com/nad-plus/ on September 2026.
- $349 from-price
The page says: “Starts At $349”
No cycle attached to the $349. Note the same page's 'Details' block describes injections, not a spray - copy-paste from the injection page.
Read from https://kinmeds.com/nad-nasal-spray/ on September 2026.
- $349 standing rate
The page says: “NAD+ Troche 200 mg Troches 30 Count | $349”
ROUTE ENUM MISMATCH: this is ORAL NAD+ itself (a troche), NOT an NMN or NR precursor. The enum's only oral value is 'oral-precursor', so it is used here for the oral route; molecule is NAD+ and a later pass must NOT treat this as NMN/NR. The figure is present only in a hidden 'Dosage Options' widget in dom.txt; the reader sees no price and a 'COMING SOON' button, so this is PRESENT, not published, and it is not an absence.
Read from https://kinmeds.com/nad-troches/ on September 2026.
Price disclosure score: 70 of 100
This scores what Kin Meds publishes about its price, and nothing else. It is not a rating of the product, the clinic, the prescriber or the value — this site has read a price page, not used a product. Across all 106 sellers in the index the scores run from 6 to 100, with a median of 72. Kin Meds sits 62 of 106.
| What is scored | What Kin Meds publishes | Points |
|---|---|---|
| An exact figure | The headline figure is an exact charge for a defined purchase, not a floor and not a first-period rate. | 30of 30 |
| A stated cadence | The seller states the interval it bills on, so a reader knows when the next charge lands. | 20of 20 |
| Visible on the page | 0 of 1 headline figures are visible to a reader; the rest sit in the page's markup only, where presence is not publication. | 0of 20 |
| A stated route | The seller states how the product is administered, in its own sentence. | 15of 15 |
| A stated dose | 1 of 3 figures state the dose they buy. | 5of 15 |
| Price disclosure score | This scores what the seller publishes about its price — not the product, the clinic, the prescriber or the value. | 70of 100 |
What Kin Meds does not publish
Each of these is a count over what was actually read, not an impression. 3 figures were read from this seller, and every sentence below is measured against that number.
- None of the 3 figures read from this seller is a standing rate charged by the calendar month.
- 1 of 3 figures were found in the page's markup but are not shown to a reader. Presence is not publication, and they are flagged rather than quoted as prices.
Figures visible to a reader on the seller’s page
2 of 3 — the rest sit in the page’s markup only
Figures stating a dose
1 of 3
Figures that resolve to a usable price
3 of 3
Source: Counted over the 3 figures read from Kin Meds’s own pages, September 2026. Each track is that figure count.
Where Kin Meds sits
68 other sellers in this index also state a SubQ and Nasal and Oral route. Ranked with them on price disclosure, Kin Meds is 49 of 69. That is a statement about how completely each one publishes a price, and about nothing else — the figures behind those rows are different kinds of number and several of them state no dose, so they are not a like-for- like price comparison and this site does not present them as one.
Boards Kin Meds appears on
The reading record
This site has read Kin Meds once, in September 2026. A movement can only be shown between two readings taken here, so there is nothing to show yet — and a single reading is a fact about this site's record, never a statement that the seller held its price.
Figures are read from Kin Meds’s own public pages and recorded with the date. What counts as a price, and why a “from” figure is recorded as a floor rather than a rate, is set out on the editorial policy page. Prices in this category move quietly, so the figure above is what the page said on September 2026 and not a promise about today.